Actively Recruiting
Safety Evaluation of VERVE-201 Using Single Ascending Doses in Adults With Refractory Hyperlipidemia
Led by Verve Therapeutics, Inc. · Updated on 2026-10-23
132
Participants Needed
18
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating VERVE-201, an investigational drug using base-editing technology designed to turn off the ANGPTL3 gene in the liver, aiming to reduce harmful cholesterol LDL-C and triglycerides in patients with refractory hyperlipidemia. This Phase 1b, open-label study focuses on assessing the safety and pharmacodynamics of VERVE-201 in this challenging patient group. Participants will be assigned to different groups some will receive a single dose of VERVE-201 in a dose-escalation cohort, others may receive a second dose if part of the re-dosing group, and some will be part of a dose-expansion cohort receiving a single dose. The drug is administered through an intravenous infusion. The study observes participants up to one year after dosing. During the trial, participants will be monitored for any treatment-related side effects and the drugs behavior in the body over 365 days. Researchers will measure changes in blood levels of ANGPTL3, LDL cholesterol, and triglycerides. Safety evaluations include tracking adverse events and serious adverse events. This comprehensive monitoring aims to understand both safety and biological effects of VERVE-201 over the study period.
CONDITIONS
Brief Title
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here